A novel bivalent morphine/heroin vaccine that prevents relapse to
... Both pre-clinical and clinical studies make feasible the use of vaccines as novel therapeutic medications to treat drug addiction. No reports to date have shown the development of structural models of opiate candidate vaccines for treating human addiction to such compounds. Here we report on the ini ...
... Both pre-clinical and clinical studies make feasible the use of vaccines as novel therapeutic medications to treat drug addiction. No reports to date have shown the development of structural models of opiate candidate vaccines for treating human addiction to such compounds. Here we report on the ini ...
Gene expression analysis of TIL rich HPV
... predominantly associated with an immune reaction (e.g., adaptive immune response, GO:0002250; lymphocyte activation, GO:0046649; positive regulation of immune system process, GO:0002684; B-cell activation, GO:0042113), whereas those expressed to a lesser extent were associated with cellular processe ...
... predominantly associated with an immune reaction (e.g., adaptive immune response, GO:0002250; lymphocyte activation, GO:0046649; positive regulation of immune system process, GO:0002684; B-cell activation, GO:0042113), whereas those expressed to a lesser extent were associated with cellular processe ...
Vaccines: `Safest of Medicines` or the `Biggest Lie`
... In general, the package inserts only refer to the persistence times for the antibodies to the disease antigens in the vaccines or, instances where no specific antibody titers can be measured (e.g., the pertussis vaccines), apparent durations for evidence of protection. Further, though antibody level ...
... In general, the package inserts only refer to the persistence times for the antibodies to the disease antigens in the vaccines or, instances where no specific antibody titers can be measured (e.g., the pertussis vaccines), apparent durations for evidence of protection. Further, though antibody level ...
Controlled Study
... eradicated in the Western world. In the first half of the twentieth century, however, it was a major public health problem. Over one-half million cases of polio were reported between 1930 and 1950, and the actual number may have been considerably higher. Because polio attacks mostly children and bec ...
... eradicated in the Western world. In the first half of the twentieth century, however, it was a major public health problem. Over one-half million cases of polio were reported between 1930 and 1950, and the actual number may have been considerably higher. Because polio attacks mostly children and bec ...
Contents - World Health Organization
... vaccine (Rotarix) should be administered orally. The company points out that unlike most other vaccines, rotavirus vaccine (Rotarix) is given orally, with an applicator that resembles a syringe. GSK has received 20 reports worldwide describing the wrong route of administration of this vaccine when i ...
... vaccine (Rotarix) should be administered orally. The company points out that unlike most other vaccines, rotavirus vaccine (Rotarix) is given orally, with an applicator that resembles a syringe. GSK has received 20 reports worldwide describing the wrong route of administration of this vaccine when i ...
Vaccination in Elite Athletes Barbara C. Ga¨rtner Tim Meyer
... vaccine (with less side effects compared with a whole-cell vaccine) with a reduced antigen content compared with childhood vaccines used for basic immunization. At present, vaccination against pertussis in adults is only feasible using a combined vaccine together with tetanus and diphtheria booster ...
... vaccine (with less side effects compared with a whole-cell vaccine) with a reduced antigen content compared with childhood vaccines used for basic immunization. At present, vaccination against pertussis in adults is only feasible using a combined vaccine together with tetanus and diphtheria booster ...
2015 DRUGS TO WATCH
... for hepatitis C virus (HCV) infection was launched in the US at the very end of 2013, and in the EU in January 2014; a Japanese regulatory filing was submitted in June 2014. January 2014’s Consensus sales forecasts for Sovaldi were $2.403 billion in 2014, rising to a peak of $9.121 billion in 2017 t ...
... for hepatitis C virus (HCV) infection was launched in the US at the very end of 2013, and in the EU in January 2014; a Japanese regulatory filing was submitted in June 2014. January 2014’s Consensus sales forecasts for Sovaldi were $2.403 billion in 2014, rising to a peak of $9.121 billion in 2017 t ...
Profectus BioSciences Announces Initiation of Clinical Trial
... evaluated in HIV‐infected subjects on stable anti‐retroviral therapy. This placebo‐controlled, dose‐escalation study is being conducted by the NIAID‐funded AIDS Clinical Trials Group at 14 sites in the US and has fully enrolled 60/60 subjects. No safety issu ...
... evaluated in HIV‐infected subjects on stable anti‐retroviral therapy. This placebo‐controlled, dose‐escalation study is being conducted by the NIAID‐funded AIDS Clinical Trials Group at 14 sites in the US and has fully enrolled 60/60 subjects. No safety issu ...
Avances en el desarrollo de productos biológicos para
... injection, flu-like symptoms) and resolved within 24 hours after injection. The data analysis of the entire sample size did not show significant differences between the vaccine and placebo at the end of six months of treatment and after the 12-month follow-up period. However, a subgroup analysis sho ...
... injection, flu-like symptoms) and resolved within 24 hours after injection. The data analysis of the entire sample size did not show significant differences between the vaccine and placebo at the end of six months of treatment and after the 12-month follow-up period. However, a subgroup analysis sho ...
JOHN F. WOLF HUMAN SUBJECTS COMMITTEES
... Dryvax in the U.S. was discontinued in 1971, and in 1983, the only active producer of vaccinia vaccine in the U.S. (Wyeth Laboratories) discontinued distribution of vaccinia vaccine for civilians. Immunity confered by the vaccine is not lifelong, and it is estimated that at least 80% of the U.S. pop ...
... Dryvax in the U.S. was discontinued in 1971, and in 1983, the only active producer of vaccinia vaccine in the U.S. (Wyeth Laboratories) discontinued distribution of vaccinia vaccine for civilians. Immunity confered by the vaccine is not lifelong, and it is estimated that at least 80% of the U.S. pop ...
Hepatitis A Virus (HAV) Fact Sheet
... Older persons are more likely to have symptoms. Symptoms usually occur abruptly and may include fever, tiredness, loss of appetite, nausea, abdominal discomfort, dark urine, or jaundice. Symptoms generally last less than 2 months; occasionally, prolonged or relapsing illness can last up to 6 months. ...
... Older persons are more likely to have symptoms. Symptoms usually occur abruptly and may include fever, tiredness, loss of appetite, nausea, abdominal discomfort, dark urine, or jaundice. Symptoms generally last less than 2 months; occasionally, prolonged or relapsing illness can last up to 6 months. ...
Ulaanbaatar, Blue Sky Tower, Oct.20
... PREVALENCE OF CANCERS CAUSED BY INFECTIOUS AGENTS: WORLDWIDE, BY COUNTRIES (2012: IARC/GLOBOCAN) [M.Plummer et al. (2016), The lancet: Global Health, http://dx.doi.org/10.2016/S.2214-109X(16)-30143-7] ...
... PREVALENCE OF CANCERS CAUSED BY INFECTIOUS AGENTS: WORLDWIDE, BY COUNTRIES (2012: IARC/GLOBOCAN) [M.Plummer et al. (2016), The lancet: Global Health, http://dx.doi.org/10.2016/S.2214-109X(16)-30143-7] ...
Powerpoint Slides - people.csail.mit.edu
... polyethylene glycol, squalene, killed and/or live viruses, viral contaminants, etc. Type 1 and type 2 diabetes, NASH, autism, asthma, food allergies, thyroiditis, vasculitis and autoimmune rheumatic diseases like lupus, rheumatoid arthritis, psoriasis and metabolic syndrome. *Classen JB, J Mol Gen ...
... polyethylene glycol, squalene, killed and/or live viruses, viral contaminants, etc. Type 1 and type 2 diabetes, NASH, autism, asthma, food allergies, thyroiditis, vasculitis and autoimmune rheumatic diseases like lupus, rheumatoid arthritis, psoriasis and metabolic syndrome. *Classen JB, J Mol Gen ...
CENTERS FOR DISEASE CONTROL AND PREVENTION
... • The Prevnar 13® Prescribing Information emphasizes that there are no data on the safety and effectiveness of Prevnar 13® when administered to immunocompromised individuals • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive the ...
... • The Prevnar 13® Prescribing Information emphasizes that there are no data on the safety and effectiveness of Prevnar 13® when administered to immunocompromised individuals • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive the ...
FAQS - Istituto Superiore di Sanità
... doses for commercialized drugs, or to test treatment combinations aimed at reaching a synergistic effect that can improve treatment efficacy. This phase usually lasts at least 2 years. 9. What is a Phase III trial? Once Phase I and II trials have given positive results, the study can move to Phase I ...
... doses for commercialized drugs, or to test treatment combinations aimed at reaching a synergistic effect that can improve treatment efficacy. This phase usually lasts at least 2 years. 9. What is a Phase III trial? Once Phase I and II trials have given positive results, the study can move to Phase I ...
Final Annual Immunisation and Vaccine Preventable Diseases
... According to the WHO Global Vaccine Action Plan 2011-2020, “Overwhelming evidence demonstrates the benefits of immunisation as one of the most successful and cost-effective health interventions known.”1 Their vision for the Decade of Vaccines (2011–2020) is of a world in which all individuals and co ...
... According to the WHO Global Vaccine Action Plan 2011-2020, “Overwhelming evidence demonstrates the benefits of immunisation as one of the most successful and cost-effective health interventions known.”1 Their vision for the Decade of Vaccines (2011–2020) is of a world in which all individuals and co ...
Awareness about cervical cancer screening among reproductive
... for the usual vaginal infections. 7 Accumulated evidence based on etiologic associations and the differential world patterns points to cervical cancer being a preventable disease. Sexual hygiene and the use of barrier contraception may largely achieve this objective but there is a need for long term ...
... for the usual vaginal infections. 7 Accumulated evidence based on etiologic associations and the differential world patterns points to cervical cancer being a preventable disease. Sexual hygiene and the use of barrier contraception may largely achieve this objective but there is a need for long term ...
Tidy_HPV_Primary_BAC_2012
... HPV testing • The development of CIN3 is not a failure of the cervical screening programme • Treating CIN3 is associated with a lower test of cure failure rate than treating CIN1 • The development of invasive cervical cancer is • We should not place the same emphasis on the development of CIN3 compa ...
... HPV testing • The development of CIN3 is not a failure of the cervical screening programme • Treating CIN3 is associated with a lower test of cure failure rate than treating CIN1 • The development of invasive cervical cancer is • We should not place the same emphasis on the development of CIN3 compa ...
Model-based calibration of the natural history of cervical cancer
... dying compared with that risk in the situation without screening, when the cancer would have become clinical. This improvement of prognosis (89.4%, 50% and 20% for FIGO IA, IB and 2+ respectively) was calibrated to reproduce recently observed stage specific survival given observed screening (Dutch C ...
... dying compared with that risk in the situation without screening, when the cancer would have become clinical. This improvement of prognosis (89.4%, 50% and 20% for FIGO IA, IB and 2+ respectively) was calibrated to reproduce recently observed stage specific survival given observed screening (Dutch C ...
4: Medicare Coverage of pneumococcal Vaccine
... asks a sample of physicians from a panel to indicate the pharmaceutical products related to their physician-patient encounters, regardless of location. The survey indicated that private physicians (excluding those in health maintenance organizations) had used only about 1.1 million doses of pneumoco ...
... asks a sample of physicians from a panel to indicate the pharmaceutical products related to their physician-patient encounters, regardless of location. The survey indicated that private physicians (excluding those in health maintenance organizations) had used only about 1.1 million doses of pneumoco ...
Tissue specific HPV expression and downregulation of local
... expressed the late (L1) gene. This transcription pattern is in good correlation with the keratinisation and diVerentiation patterns of the two epithelia: perianal biopsies preferentially expressed K16 and K17 while penile warts mainly expressed K10, markers of parakeratotic and orthokeratotic epithe ...
... expressed the late (L1) gene. This transcription pattern is in good correlation with the keratinisation and diVerentiation patterns of the two epithelia: perianal biopsies preferentially expressed K16 and K17 while penile warts mainly expressed K10, markers of parakeratotic and orthokeratotic epithe ...
Pharmacy Monthly Newsletter
... formation of the bacterial cell wall and disrupts bacterial cell membrane function. It may prove that the additive mechanisms of action seen with telavancin speed bacterial killing while also reducing the risks of inducing resistance to telavancin or cross-resistance with other antibiotics. Gardasil ...
... formation of the bacterial cell wall and disrupts bacterial cell membrane function. It may prove that the additive mechanisms of action seen with telavancin speed bacterial killing while also reducing the risks of inducing resistance to telavancin or cross-resistance with other antibiotics. Gardasil ...
Cervarix-H-C-721-P46-0088: EPAR - EMA
... On 7 September 2015, the MAH submitted the immunogenicity and safety results of study HPV-071 from Month 18 up to Month 24 for Cervarix, in accordance with Article 46 of Regulation (EC) No1901/2006, as amended. ...
... On 7 September 2015, the MAH submitted the immunogenicity and safety results of study HPV-071 from Month 18 up to Month 24 for Cervarix, in accordance with Article 46 of Regulation (EC) No1901/2006, as amended. ...
Update on herpes zoster vaccination
... for the chickenpox (varicella) vaccine for children—which is different from the vaccine for adults—state that ASA should not be used to treat fever related to vaccinations in children because of the rare, but possible, association with Reye syndrome. This association does not exist with adults. Ther ...
... for the chickenpox (varicella) vaccine for children—which is different from the vaccine for adults—state that ASA should not be used to treat fever related to vaccinations in children because of the rare, but possible, association with Reye syndrome. This association does not exist with adults. Ther ...
Gardasil
Gardasil (Merck & Co.), also known as Gardisil or Silgard or recombinant human papillomavirus vaccine [types 6, 11, 16, 18], is a vaccine for use in the prevention of certain strains of human papillomavirus (HPV), specifically HPV types 6, 11, 16 and 18. HPV types 16 and 18 cause an estimated 70% of cervical cancers, and are responsible for most HPV-induced anal, vulvar, vaginal, and penile cancer cases. HPV types 6 and 11 cause an estimated 90% of genital warts cases. Though it does not treat existing infection, vaccination is still recommended for HPV positive individuals, as it may protect against one or more different strains of the disease. The HPV strains that Gardasil protects against are sexually transmitted.It was approved in the US on June 8, 2006 by the U.S. Food and Drug Administration (FDA). In 2008, Gardasil was approved in 41 of U.S. states. The Gardasil vaccine has also been approved in 120 other countries. The FDA recommends vaccination before adolescence and potential sexual activity.In December 2014, the FDA approved a nine-valent Gardasil-based vaccine, Gardasil 9, to protect against infection with the strains covered by the first generation of Gardasil as well as five other HPV strains responsible for 20% of cervical cancers (HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58).